Dasatinib (Figure 8), a small molecule inhibitor of Src and abl proteins, has been approved for imatinib refractory chronic myelogenous leukemia and bcr–abl positive acute lymphoblastic leukemia treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.